Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Lymphoma 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Lymphoma, Large B-Cell, Diffuse 29Prostatic Neoplasms 28Lymphoma, Follicular 15Leukemia 15Lymphoma, Non-Hodgkin 13Hodgkin Disease 11Burkitt Lymphoma 10Leukemia, Biphenotypic, Acute 8Recurrence 6Neoplasms 6Neoplasm Metastasis 6Lymphoma, Large-Cell, Anaplastic 6Lymphoma, B-Cell 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 4Multiple Myeloma 4Immunoblastic Lymphadenopathy 4Hemangioma 4Dendritic Cell Sarcoma, Interdigitating 4Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell, Marginal Zone 3Breast Neoplasms 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neurotoxicity Syndromes 2Neoplasm, Residual 2

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 100liposomal doxorubicin 100Cyclophosphamide 94Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 39Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × Prednisolone × Clear all
NCT06421935 2026-03-24

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

EMD Serono

Phase 1 Active not recruiting
141 enrolled
Gynecologic

Ovarian Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Eisai Inc.

Phase 1/2 Recruiting
182 enrolled
BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡